{"id":41,"date":"2014-07-25T13:24:12","date_gmt":"2014-07-25T13:24:12","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/?p=41"},"modified":"2021-08-23T12:45:39","modified_gmt":"2021-08-23T07:15:39","slug":"oncology-theraopeutics-making-big-in-coming-years","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years","title":{"rendered":"Oncology Therapeutics Making Big in Coming Years"},"content":{"rendered":"\n

The industry’s 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche’s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of the combined value of the 10 biggest-selling products.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
Drug Name<\/strong><\/span><\/td>Company<\/strong><\/span><\/td><\/tr>
Rituxan\/MabThera<\/strong><\/td>Roche, Pharmstandard<\/td><\/tr>
Avastin<\/strong><\/td>Roche<\/td><\/tr>
Herceptin<\/strong><\/td>Roche<\/td><\/tr>
Gleevec<\/strong><\/td> Novartis<\/td><\/tr>
Alimta<\/strong><\/td>Eli Lilly<\/td><\/tr>
Velcade<\/strong><\/td>Johnson & Johnson, Takeda,Pharmstandard<\/td><\/tr>
Erbitux<\/strong><\/td>Merck KGaA, Bristol-Myers Squibb<\/td><\/tr>
Lupron, Eligard<\/strong><\/td>AbbVie and Takeda; Sanofi   and Astellas Pharma<\/td><\/tr>
Zytiga<\/strong><\/td>Johnson & Johnson<\/td><\/tr>
Revlimid<\/strong><\/td>\n

Celgene, Pharmstandard<\/p>\n<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Rituxan is developed by Roche’s Genentech which is the first monoclonal antibody treatment for cancer. And even after 15 years on the market, it continues to see its sales grow, up 6% for Roche in 2013. The drug is also approved to treat a number of cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL), it also works against rheumatoid arthritis and generates about $1.2 billion a year in that category.<\/p>\n\n\n\n

By comparing the sales of all the drugs the Roche company becomes the king of all the Pharmaceutical Companies involved in making oncology drugs.<\/p>\n\n\n\n

Let\u2019s have a look over the ranking on the basis of oncology sales 2013.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Roche has topped the ranking by its top selling drugs, followed by Amgen, Novartis, Celgene, Johnson and Johnson, Lily, Astrazeneca, Merck, BMS and Takeda.<\/p>\n\n\n\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

The industry’s 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche’s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of the combined value of the 10 biggest-selling products. […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[56,69,100,108,130,155,228,229,234,270,292,341,366,395,423,471,518,521,524,553,554,577,578,598,613],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-41","post","type-post","status-publish","format-standard","hentry","category-articles","tag-abbvie","tag-alimta","tag-avastin","tag-best-selling-oncology-drugs","tag-bristol-myers-squibb","tag-celgene","tag-eli-lilly","tag-eligard","tag-erbitux","tag-gleevec","tag-herceptin","tag-johnson-johnson","tag-lupron","tag-merck","tag-novartis","tag-pharmstandard","tag-revlimid","tag-rituxanmabthera","tag-roche","tag-taked","tag-takeda","tag-top-10-companies-oncology","tag-top-10-oncology-drugs","tag-velcade","tag-zytiga","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nOncology Therapeutics Market Opportunities | Oncology Therapeutics<\/title>\n<meta name=\"description\" content=\"The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology Therapeutics Market Opportunities | Oncology Therapeutics\" \/>\n<meta property=\"og:description\" content=\"The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-25T13:24:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-23T07:15:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/top-10-oncology-drug-sales.png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oncology Therapeutics Market Opportunities | Oncology Therapeutics","description":"The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years","og_locale":"en_US","og_type":"article","og_title":"Oncology Therapeutics Market Opportunities | Oncology Therapeutics","og_description":"The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan.....","og_url":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-07-25T13:24:12+00:00","article_modified_time":"2021-08-23T07:15:39+00:00","og_image":[{"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/top-10-oncology-drug-sales.png","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years","url":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years","name":"Oncology Therapeutics Market Opportunities | Oncology Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/top-10-oncology-drug-sales.png","datePublished":"2014-07-25T13:24:12+00:00","dateModified":"2021-08-23T07:15:39+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/oncology-theraopeutics-making-big-in-coming-years#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23124529\/top-10-oncology-drug-sales.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23124529\/top-10-oncology-drug-sales.png","width":581,"height":342},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alimta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Avastin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Best Selling Oncology Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eligard<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Erbitux<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gleevec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Herceptin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Johnson & Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmstandard<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Revlimid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rituxan\/MabThera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Taked<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Top 10 Companies oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Top 10 Oncology Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Velcade<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Zytiga<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Alimta<\/span>","<span class=\"advgb-post-tax-term\">Avastin<\/span>","<span class=\"advgb-post-tax-term\">Best Selling Oncology Drugs<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Eligard<\/span>","<span class=\"advgb-post-tax-term\">Erbitux<\/span>","<span class=\"advgb-post-tax-term\">Gleevec<\/span>","<span class=\"advgb-post-tax-term\">Herceptin<\/span>","<span class=\"advgb-post-tax-term\">Johnson & Johnson<\/span>","<span class=\"advgb-post-tax-term\">Lupron<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pharmstandard<\/span>","<span class=\"advgb-post-tax-term\">Revlimid<\/span>","<span class=\"advgb-post-tax-term\">Rituxan\/MabThera<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Taked<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Top 10 Companies oncology<\/span>","<span class=\"advgb-post-tax-term\">Top 10 Oncology Drugs<\/span>","<span class=\"advgb-post-tax-term\">Velcade<\/span>","<span class=\"advgb-post-tax-term\">Zytiga<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 25, 2014","modified":"Updated on Aug 23, 2021"},"absolute_dates_time":{"created":"Posted on Jul 25, 2014 1:24 pm","modified":"Updated on Aug 23, 2021 12:45 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/41","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=41"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/41\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=41"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=41"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=41"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=41"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}